<?xml version="1.0" encoding="UTF-8"?>
<p id="par0155">AG7088 (
 <bold>56</bold>, peptide derivative), a potent inhibitor of rhinovirus 3C
 <sup>pro</sup> with Michael acceptor functionality, failed to inhibit SARS-CoV 3CL
 <sup>pro</sup>
 <xref rid="bib0525" ref-type="bibr">[105]</xref>. However, a series of AG7088 analogs were reported to combat CoVs by targeting 3CL
 <sup>pro</sup>
 <xref rid="bib0530" ref-type="bibr">[106]</xref>. The screening of peptidomimetics (
 <bold>57–60</bold>; see 
 <xref rid="fig0045" ref-type="fig">Fig. 9</xref>) which contains a Michael acceptor group, (i.e., α,β-unsaturated carbonyl) showed moderate anti-CoV activities 
 <xref rid="bib0535" ref-type="bibr">107</xref>, 
 <xref rid="bib0540" ref-type="bibr">108</xref>, 
 <xref rid="bib0545" ref-type="bibr">109</xref>. Enterovirus inhibitors 
 <bold>61</bold>, 
 <bold>62</bold>, and 
 <bold>63</bold>, were recently shown to inhibit MERS-CoV with EC
 <sub>50</sub> values ranging from 1.7 to 4.7 μM 
 <xref rid="bib0550" ref-type="bibr">[110]</xref>. These inhibitors provide an excellent starting point for the development of natural substrate mimicking (or peptidomimetics) compounds against SARS- and MERS-CoV 3CL
 <sup>pro</sup>. Benzotriazole derivatives (
 <bold>64</bold>,
 <bold>65</bold>) that have an activated carbonyl functionality displayed inhibition against both SARS-CoV 3CL
 <sup>pro</sup> and MERS-CoV 3CL
 <sup>pro</sup>
 <xref rid="bib0555" ref-type="bibr">[111]</xref>.
</p>
